2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1890

Functional Disability and Its Predictors in Systemic Sclerosis: A Study from the Desscipher Project within the European Scleroderma Trials and Research Group

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1578

Functional Screening of Micrornas Using the Inhibitor Library Identified Micrornas to Regulate Expression of MMP-3 and IL-6 in Rheumatoid Arthritis Synovial Fibroblasts

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1257

Gender Differences in Ankylosing Spondylitis Patients Treated with Anti-TNF in Daily Practice with Ten Year Follow up

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1198

Gene Enrichment Analysis Identifies Active CD40-CD40L Signaling in Early and Established Rheumatoid Arthritis

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1565

Gene Modules Correlated with Disease Activity and Abatacept Treatment Identified with Weighted Gene Co-Expression Network Analysis of CD4+ T Cell Subsets of RA

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1803

General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1485

Generation of New Carotid Plaque Is Determined By the Prexisting Carotid Atherosclerosis and Ongoning Disease Activity of Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1837

Genetic Susceptibility Loci for Systemic Lupus Erythematosus in the Dominican Republic Population

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1103

Gingival Tissue-Derived MSC Cells (GMSC) Suppress Osteoclastogenesis and Bone Erosion in Collagen-Induced Arthritis Thought CD73 Signal Pathway

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1451

Glutamine Metabolism Plays a Crucial Role in the Pathogenesis of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1268

Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment – Results from a Randomized Controlled Clinical Trial.

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1810

Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1224

Healthcare and Research Priorities of Adolescents and Young Adults with Systemic Lupus Erythematosus: A Mixed-Methods Study

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1235

Healthcare Utilization and Multimorbidities Among Adult Patients with Juvenile Idiopathic Arthritis

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1916

Heightened MAIT Cell Sensitivity to MR1 Ligands Could Impact Control of Dysbiosis in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].